We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck KGaA, Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab
Merck KGaA, Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab
German drugmaker Merck KGaA and Pfizer have received breakthrough therapy designation for immunotherapy avelumab for second-line treatment of metastatic Merkel cell carcinoma.